List of Mavyret drug patents

Mavyret is owned by Abbvie Inc.

Mavyret contains Glecaprevir; Pibrentasvir.

Mavyret has a total of 20 drug patents out of which 0 drug patents have expired.

Mavyret was authorised for market use on 10 June, 2021.

Mavyret is available in pellets;oral dosage forms.

Mavyret can be used as treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg, treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg, treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg.

Drug patent challenges can be filed against Mavyret from March, 2022.

The generics of Mavyret are possible to be released after 24 December, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8648037 ABBVIE INC Macrocyclic proline derived HCV serine protease inhibitors
Jan, 2032

(8 years from now)

US8937150 ABBVIE INC Anti-viral compounds
May, 2032

(9 years from now)

USRE48923 ABBVIE INC Crystal forms
May, 2035

(12 years from now)

US9321807 ABBVIE INC Crystal forms
Jun, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028937 ABBVIE INC Anti-viral compounds
Jun, 2030

(7 years from now)

US10039754 ABBVIE INC Anti-viral compounds
Jun, 2030

(7 years from now)

US9586978 ABBVIE INC Anti-viral compounds
Nov, 2030

(7 years from now)

US10028937

(Pediatric)

ABBVIE INC Anti-viral compounds
Dec, 2030

(7 years from now)

US10039754

(Pediatric)

ABBVIE INC Anti-viral compounds
Dec, 2030

(7 years from now)

US9586978

(Pediatric)

ABBVIE INC Anti-viral compounds
May, 2031

(8 years from now)

US8648037

(Pediatric)

ABBVIE INC Macrocyclic proline derived HCV serine protease inhibitors
Jul, 2032

(9 years from now)

US8937150

(Pediatric)

ABBVIE INC Anti-viral compounds
Nov, 2032

(9 years from now)

US10286029 ABBVIE INC Method for treating HCV
Mar, 2034

(11 years from now)

US11484534 ABBVIE INC Methods for treating HCV
Mar, 2034

(11 years from now)

US10286029

(Pediatric)

ABBVIE INC Method for treating HCV
Sep, 2034

(11 years from now)

US11484534

(Pediatric)

ABBVIE INC Methods for treating HCV
Sep, 2034

(11 years from now)

USRE48923

(Pediatric)

ABBVIE INC Crystal forms
Nov, 2035

(12 years from now)

US9321807

(Pediatric)

ABBVIE INC Crystal forms
Dec, 2035

(12 years from now)

US11246866 ABBVIE INC Solid pharmaceutical compositions for treating HCV
Jun, 2036

(13 years from now)

US11246866

(Pediatric)

ABBVIE INC Solid pharmaceutical compositions for treating HCV
Dec, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 3, 2022
M Apr 10, 2023
New Dosing Schedule (D) Sep 26, 2022
Orphan Drug Exclusivity (ODE) Jun 10, 2028
Pediatric Exclusivity (PED) Mar 26, 2023

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: March, 2022

Market Authorisation Date: 10 June, 2021

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg

Dosage: PELLETS;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in